InvestorsHub Logo
Followers 229
Posts 21432
Boards Moderated 2
Alias Born 08/03/2006

Re: Honeycomb777 post# 10695

Friday, 07/21/2017 5:45:08 AM

Friday, July 21, 2017 5:45:08 AM

Post# of 20617
$INNV Improving. We can handle it. Figure close to 8M per month burn. But need to adjust a bit based on the pps. 292 authorized. Nearest RS would be mid to later next year or an authorized increase (my guess). Bring in enough revenue to start making a difference, then buy backs are possible.

You're in or you're out. I'm in for moving towards cash positive and then getting the share structure under control. They're moving in the right direction.

https://finance.yahoo.com/quote/INNV?p=INNV


Innovus Pharma’s Partner Luminarie Receives Approval for Zestra® for Female Sexual Arousal Disorder as a Medical Device I from Australia’s Therapeutic Goods Administration.

Innovus Pharmaceuticals, Inc. , an emerging over-the-counter consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today that its partner Luminarie Pty Ltd received approval to commercialize ...



Marketwired•29 days ago

The Life Sciences Report Examines How a Fast-Growing Pharma Company Prepares to Launch OTC Nasal Spray.

A San Diego-based pharmaceutical company that focuses on over-the-counter medications reported strong Q1/17 results and expects to begin marketing a nasal spray by the end of the year.Included in this ...



Marketwired•last month

Innovus Joins Eli Lilly and Novartis in the Race to Develop Products for Oncology (Cachexia) -- SECFilings.com.

SECFilings.com, a leading financial news and information portal offering free real time public filing alerts, recently published an article discussing Innovus Pharmaceuticals' recent entry into the oncology ...




Business Wire•last month

Innovus Pharma to Enter the Oncology Supportive Care Market With an Exclusive License to Two GRAS-Listed OTC Compounds for Cachexia and Muscle Growth and Repair From the University of Iowa Research Foundation.

Innovus Pharmaceuticals, Inc. , an emerging over-the-counter consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today its plans to enter the oncology supportive care OTC market with ...



Business Wire•2 months ago

Innovus Pharma Announces Positive Pre-Clinical Synergistic Effects of Vesele® in Combination with Sildenafil (Viagra®) on Nitric Oxide Production.

Innovus Pharmaceuticals, Inc. , an emerging over-the-counter consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today the first set of its pre-clinical results on the combination use ...



Accesswire•2 months ago

SeeThruEquity Issues Update on Innovus Pharmaceuticals (INNV) with Price Target of $0.65.

NEW YORK, NY / ACCESSWIRE / May 26, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued ...

Business Wire•2 months ago

Innovus Pharma Launches AllerVarx, a Clinically Proven Supplement for the Relief of Allergy Symptoms, in the United States.

Innovus Pharmaceuticals, Inc. , an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the launch of AllerVarx™ in the U.S.

Business Wire•2 months ago

Innovus Pharma Signs Exclusive License and Distribution Agreement with Luminarie in Australia, New Zealand and the Philippines for Zestra® for Female Sexual Arousal Disorder and Zestra Glide® for Female Lubrication.

Innovus Pharmaceuticals, Inc. , an emerging over-the-counter consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today the signing of an exclusive license and distribution agreement ...


Marketwired•2 months ago

Innovus Makes Strides Toward Goal of Tripling Revenue in 2017 -- SECFilings.com.

SECFilings.com, a leading financial news and information portal offering free real time public filing alerts, recently published an article discussing Innovus Pharmaceuticals' recent financial results ...



Business Wire•2 months ago

Innovus Pharma Files Its Product License Application in Canada for the Commercialization of Vesele® as a Natural Health Product to Help Improve Symptoms of Sexual Dysfunction.

Innovus Pharmaceuticals, Inc. today announced that the Company filed its Product License Application with Health Canada as a Natural Health Product to market its current best-selling product Vesele® with the indication to “Help Improve Symptoms of Sexual Dysfunction.” If accepted by Health Canada, Vesele® will be available over-the-counter in 120 capsule bottles and will not require a prescription....

As long as this continues to improve from here we could be looking pretty good in a couple quarters.




From the last 10Q

10-Q Our Products
We currently generate revenue from 18 products in the U.S. and six in international countries, as follows:


1. Vesele® for promoting sexual and health (U.S. and U.K.);

2.Zestra® for female arousal (U.S., U.K., Denmark, Canada, Morocco, the UAE and South Korea);

3. Zestra Glide® (U.S, Canada and the MENA countries);

4. EjectDelay® indicated for the treatment of premature ejaculation (U.S. and Canada);

5. Sensum+® to alleviate reduced penile sensitivity (U.S., U.K. and Morocco);

6. Beyond Human® Testosterone Booster;

7. Beyond Human® Ketones;

8. Beyond Human® Krill Oil;

9. Beyond Human® Omega 3 Fish Oil;

10. Beyond Human® Vision Formula;

11. Beyond Human® Blood Sugar;

12. Beyond Human® Colon Cleanse;

13. Beyond Human® Green Coffee Extract;

14. Beyond Human® Growth Agent;

15. RecalMax™ for brain health;

16. Androferti® (U.S. and Canada) for the support of overall male reproductive health and sperm quality;

17. UriVarx™ for bladder health; and

18. ProstaGorx™ for prostate health.



In addition, we currently expect to launch in the U.S. the following products in 2017, subject to the applicable regulatory approvals, if required:

1. AllerVarx™ for the management of allergy symptoms (first half of 2017);

2. FlutiCare™ for allergic rhinitis (second half of 2017);

3. Xyralid™ for the relief of the pain and symptoms caused by hemorrhoids (second half of 2017);

4. AndroVit™ for men's health (second half of 2017);

5. Urocis™ XR for urinary tract infections (second half of 2017);

6. Apeaz™ for arthritis related pain (second half of 2017);

7. ArthriVarx™ for joint health (second half of 2017); and

8. PEVarx™ for extension of sexual intercourse time (second half of 2017).


Pipeline Products



ProstaGorx™. ProstaGorx™ is a clinical strength, multi-response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in preventing prostate issues in the future. We recently launched this product in May 2017.



AllerVarx™. On December 15, 2016, we entered into an exclusive license and distribution agreement with NTC S.r.l (Italy) to distribute and commercialize AllerVarx™ in the U.S. and Canada. AllerVarx™ is a proprietary modified release bilayer tablet for the management of allergy symptoms. We expect to launch this product in the first half of 2017.



FlutiCare™ (fluticasone propionate nasal spray). Innovus acquired the worldwide rights to market and sell the FlutiCare™ brand (fluticasone propionate nasal spray) and the related third-party manufacturing agreement for the manufacturing of FlutiCare™ from Novalere FP, Inc. in February 2015 (see Note 3). The Over-the-Counter (“OTC”) Abbreviated New Drug Application (“ANDA”) filed at the end of 2014 by the third-party manufacturer, who is currently selling the prescription version of the drug, with the U.S. Food and Drug Administration (“FDA”), subject to FDA approval, may allow us to market and sell FlutiCare™ OTC in the U.S. An ANDA is an application for a U.S. generic drug approval for an existing licensed medication or approved drug. A prescription ANDA (“RX ANDA”) is for a generic version of a prescription pharmaceutical and an OTC ANDA is for a generic version of an OTC pharmaceutical. Due to the delay in approval of the third-party manufacturer’s OTC ANDA by the FDA, in May 2017, we announced a commercial relationship with a different third-party manufacturer (West-Ward Pharmaceuticals International Limited or “WWPIL”) who has an FDA approved OTC ANDA for fluticasone propionate nasal spray under which they have agreed to manufacture our FlutiCare™ OTC product for sale in the U.S. (see Note 9). We expect to launch our FlutiCare™ OTC product in the U.S. in the second half of 2017.




Xyralid™. Xyralid™ is an OTC FDA monograph compliant drug containing the active drug ingredient lidocaine and indicated for the relief of the pain and symptoms caused by hemorrhoids. We expect to launch this product in the second half of 2017.



Urocis™ XR. On October 27, 2015, we entered into an exclusive distribution agreement with Laboratorios Q Pharma (Spain) to distribute and commercialize Urocis™ XR in the U.S. and Canada. Urocis™ XR is a proprietary extended release of Vaccinium Marcocarpon (cranberry) shown to provide 24-hour coverage in the body in connection with urinary tract infections in women. We expect to launch this product in the second half of 2017.



AndroVit™. On October 27, 2015, we entered into an exclusive distribution agreement with Laboratorios Q Pharma (Spain) to distribute and commercialize AndroVit™ in the U.S. and Canada. AndroVit™ is a proprietary supplement to support overall prostate and male sexual health currently marketed in Europe. AndroVit™ was specifically formulated with ingredients known to support normal prostate health and vitality and male sexual health. We expect to launch this product in the second half of 2017.



Apeaz™. We developed our proprietary product Apeaz™, which is an OTC FDA monograph compliant drug containing the active drug ingredient methyl salicylate and indicated for the minor aches and pains of muscles and joints associated with simple backaches, arthritis, strains, bruises and sprains. We expect to launch this product in the second half of 2017.



ArthriVarx™. This nutritional supplement is designed to relieve the pain associated with arthritis. We expect to launch this product in the second half of 2017.



PEVarx™. This product is designed and tested in several hundred men to extend the length of sexual intercourse. We expect to launch this product in the second half of 2017.



See PAGES 25 - 27 ALSO
https://www.sec.gov/Archives/edgar/data/1411879/000165495417004629/innv10q_mar312017.htm

CC transcript...
https://seekingalpha.com/article/4072852-innovus-pharmaceuticals-innv-bassam-damaj-q2-2017-results-earnings-call-transcript

"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.